Personalizing Therapy for Patients With CML

Michael J. Mauro, MD

Video Categories: CML

Dr. Mauro addresses the debate over selecting first line therapy with three approved agents available.
January 20, 2016

“Steminess” Qualities of Cells

Dr Wainberg and Dr Gerson discuss features of stem cells and how in understanding their features they can be targeted for therapeutics.

July 25, 2018

Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries

Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.